Clinical trials: Digestive Diseases
Gastroesophageal Reflux
Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy
The purpose of this study is to determine if patients with well-controlled heartburn symptoms on twice-daily proton pump inhibitor therapy remain well-controlled after stepping down to once-daily (QD) dexlansoprazole modified…
- Trial name
- NCT00847808
- Testing
- Dexlansoprazole MR QD
- Where
- 52 sites in United States
- Volunteers
- 178 people
- Sponsor
- Takeda
Gastric Cancer, Gastroesophageal Junction Cancer
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal…
- Trial name
- NCT03221426
- Testing
- Pembrolizumab, Cisplatin, Capecitabine
- Where
- 171 sites in United States, Belgium and 22 more
- Volunteers
- 1,007 people
- Sponsor
- Merck Sharp & Dohme LLC
Idiopathic Gastroparesis
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopathic gastroparesis severity in adult subjects.
- Trial name
- NCT06899217
- Testing
- CIN-102 Dose 15mg, CIN-102 Dose 10mg
- Where
- 85 sites in United States
- Volunteers
- 416 people
- Sponsor
- CinDome Pharma, Inc.
Obesity
Safety and Efficacy of APD356 in the Treatment of Obesity
This is a research study of an investigational drug, APD356, a novel, selective 5-HT2c receptor agonist, in clinical development as a potential treatment for obesity.
- Trial name
- NCT00116740
- Testing
- APD356
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Colorectal Cancer
A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma
This is an observational study designed to follow patients with metastatic or locally advanced and unresectable colorectal cancer who are receiving Avastin in combination with chemotherapy and whose cancer has been either…
- Trial name
- NCT00097578
- Where
- United States
- Volunteers
- 1,953 people
- Sponsor
- Genentech, Inc.
Crohn's Disease
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
The purpose of this study is to evaluate the efficacy of guselkumab in healing of all layers of the digestive tract (transmural healing) with the help of a score called Magnetic Resonance Index of Activity (MaRIA) based on a scan…
- Trial name
- REASON (NCT06408935)
- Testing
- Guselkumab
- Where
- 84 sites in United States, Australia and 12 more
- Volunteers
- 120 people
- Sponsor
- Janssen-Cilag Ltd.
Hepatitis B, Chronic, Hepatitis D
A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection
This is a randomized, double-blinded, placebo-controlled, multi center, dose ranging study of safety and efficacy in both volunteers with chronic hepatitis B virus infection and in volunteers with hepatitis D virus coinfection.
- Trial name
- NCT04847440
- Testing
- ATI-2173, Viread, AB-729
- Where
- 2 sites in Moldova, Ukraine
- Volunteers
- 40 people
- Sponsor
- Antios Therapeutics, Inc
Chronic Hepatitis C
Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study
The interferon-free combination regimen of paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in…
- Trial name
- NCT02798315
- Volunteers
- 40 people
- Sponsor
- AbbVie
Crohn Disease
BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity
Primary Objective: The primary objective of this trial is to compare the clinical efficacy of BI 695501 with EU-approved Humira® in patients with active Crohn's disease (CD).
- Trial name
- NCT02871635
- Testing
- BI 695501, HUMIRA
- Where
- 92 sites in United States, Belarus and 12 more
- Volunteers
- 147 people
- Sponsor
- Boehringer Ingelheim
Gastrointestinal Disease, Colorectal Cancer
Randomized Controlled Study Comparing Colon Evaluation With The Pure-Vu System To A Standard Colonoscopy In Patients Who Are High Risk For Inadequate Bowel Preparation
The primary objective of this multi-center, prospective, randomized controlled trial is to evaluate the bowel cleansing after Pure-Vu use in outpatient subjects at high risk for inadequate colon preparation as compare to standard…
- Trial name
- RESCue (NCT04285008)
- Testing
- Pure-Vu System
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Motus GI Medical Technologies Ltd
Gastroparesis, Diabetes Mellitus
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01
This study will evaluate the safety and efficacy of relamorelin compared to placebo in participants with diabetic gastroparesis. Participants will report daily severity scores of their diabetic gastroparesis symptoms.
- Trial name
- NCT03285308
- Testing
- Relamorelin
- Where
- 216 sites in United States, Australia and 12 more
- Volunteers
- 336 people
- Sponsor
- Allergan
Liver Fibrosis, Hepatic Cirrhosis
A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.
The purpose of this study is to measure the safety, tolerability, and the way the body absorbs, distributes, and metabolises AZD2389 as compared to placebo in participants with liver fibrosis and compensated cirrhosis.
- Trial name
- BORANA (NCT06750276)
- Testing
- AZD2389
- Where
- 9 sites in United States, Puerto Rico and 1 more
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Ulcerative Colitis
Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis
The purpose of this study is to compare two different dosing regimens of phosphatidylcholine versus placebo for the induction of remission in ulcerative colitis patients non-responsive to standard mesalamine treatment.
- Trial name
- PROTECT-1 (NCT02142725)
- Testing
- LT-02
- Where
- Germany
- Volunteers
- 468 people
- Sponsor
- Dr. Falk Pharma GmbH
Metastatic Colorectal Cancer
Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer
The purpose of this study is to determine if Cediranib when added to chemotherapy is more effective than chemotherapy alone in prolonging life expectancy and slowing disease progression in patients with previously untreated…
- Trial name
- HORIZON II (NCT00399035)
- Testing
- Cediranib, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), XELOX (Capecitabine and Oxaliplatin)
- Where
- 90 sites in Argentina, Australia and 13 more
- Volunteers
- 1,254 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn
The purpose of this study is to determine the long-term safety profile of daily treatment with dexlansoprazole MR in subjects with gastroesophageal reflux disease.
- Trial name
- NCT00255190
- Testing
- Dexlansoprazole MR
- Where
- 181 sites in United States
- Volunteers
- 591 people
- Sponsor
- Takeda
Hepatitis C, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin
This study will evaluate the efficacy, safety and tolerability of PEGASYS plus ribavirin in patients with CHC who could not tolerate or were not responsive to 12 weeks of therapy with PEG-Intron plus ribavirin.
- Trial name
- NCT00087568
- Testing
- Ribavirin, peginterferon alfa-2a [Pegasys]
- Where
- 25 sites in United States
- Volunteers
- 57 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Hepatocellular
Oxaliplatin in Unresectable Hepatocellular Carcinoma
Primary: To determine the Tumor Response Rate of patients with hepatocellular carcinoma treated with the combination chemotherapy of Eloxatin+5-Fluorouracil/Leucovorin Secondary: Safety and tolerability of this regimen in these…
- Trial name
- NCT00280618
- Testing
- Oxaliplatin
- Sponsor
- Sanofi
Glioblastoma Multiforme (GBM), Pancreatic Ductal Adenocarcinoma (PDAC)
Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
The goal of this Phase I clinical trial is to evaluate how the imaging drug 203Pb- RMX-VH-PIB distributes in the body and how much radiation different organs receive in patients with glioblastoma multiforme (GBM) or pancreatic…
- Trial name
- RMX-VH (NCT07733674)
- Testing
- 203Pb-RMX-VHPIB injection, SPECT/CT Imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Radiomedix, Inc.
Carcinoma, Hepatocellular
A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).
This study will look at whether our drug (sorafenib) in combination with chemotherapy delivered directly into your tumor using beads (DC Bead) will slow the progression of the disease.
- Trial name
- NCT00855218
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 107 sites in United States, Australia and 11 more
- Volunteers
- 307 people
- Sponsor
- Bayer
Acute Liver Failure, Fulminant Hepatic Failure
Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF)
This phase 2 study is developed to evaluate the effect of ELAD on overall survival (OS) in subjects with acute liver failure (ALF) compared to matched historical controls.
- Conditions
- Acute Liver Failure, Fulminant Hepatic Failure, Primary Graft Non-Function, Surgically-Induced Liver Failure
- Trial name
- NCT01875874
- Testing
- ELAD
- Where
- 18 sites in United States
- Volunteers
- 8 people
- Sponsor
- Vital Therapies, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.